10 research outputs found

    Preparations of longitudinal smooth muscle isolated from normal (A) or DNBS-treated rats (colitis) (B).

    No full text
    <p>Effects of increasing concentrations of A804598 (0.001–10 µM) on contractions evoked by sES (0.5 ms, 10 Hz, 30 mA, 10 s) in preparations maintained in standard Krebs solution. Each column represents the mean±SEM obtained from 6 experiments. *P<0.05, versus control (CON).</p

    Double immunostaining showing the expression of P2X7 receptors (green) and the glial marker GFAP (red) in myenteric plexus of colonic cryosections from control (A; normal) and DNBS-treated (B; colitis) rats.

    No full text
    <p>Nuclei were stained with TOTO-3. Scale bar: 21 µm. Enlarged view of GFAP<sup>+</sup> and P2X7<sup>+</sup> cells in the myenteric ganglia of normal and colitis rats from boxed area in overlay (scale bar = 10 µm). LM, longitudinal muscle; CM, circular muscle; MG, myenteric ganglia. Isotype fluorescent image was obtained by labeling with Alexa Fluor 555 conjugated secondary antibody in presence of normal mouse antiserum instead of the primary antibody.</p

    Double-staining immunohistochemistry showing the distribution of P2X7 receptors (green) and the neuronal marker HuC/D (red) in the myenteric plexus of colonic cryosections from control (A; normal) or DNBS-treated (B; colitis) rats.

    No full text
    <p>Nuclei were stained with TOTO-3. Scale bar: 21 µm. Enlarged view of HuC/D<sup>+</sup> and P2X7<sup>+</sup> cells in the myenteric ganglia of normal and colitis rats from boxed area in overlay (scale bar = 10 µm). LM, longitudinal muscle; CM, circular muscle; MG, myenteric ganglia. Isotype fluorescent image was obtained by labeling with streptavidin conjugated with Alexa Fluor 555 in presence of normal mouse antiserum instead of the primary antibody.</p

    DataSheet1_Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy.pdf

    No full text
    Introduction: The disease activity associated with the drug-utilization patterns of biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) is poorly investigated in real-world studies on rheumatoid arthritis (RA) patients. To investigate the relationship between biologic DMARD initiation/discontinuations in RA patients identified in the healthcare administrative databases of Tuscany and the Disease Activity Score 28 (DAS28) reported in the medical charts.Methods: This retrospective population-based study included RA’s first-ever biologic DMARD users of the Pisa University Hospital from 2014 to 2016. Patients were followed up until 31 December 2019. We evaluated the DAS28 recorded before (T0) and after (T1) the biologic DMARD initiation and before (TD0) and after (TD1) discontinuations. Patients were classified as “off-target” (DAS28 > 3.2) or “in-target” (DAS28 ≤ 3.2). We described the disease activity trends at initiation and discontinuation.Results: Ninety-five users were included (73 women, mean age 59.6). Among 70 patients (74%) with at least three DAS28 measures, 28 (40.0%) were off-target at T0 and 38 (54.3%) in-target at T1. Thirty-three (47%) patients had at least one discontinuation, among those with at least three DAS28 assessments. In the disease activity trend, disease stability or improvement was observed in 28 out of 37 (75.7%) patients at initiation and in 24 out of 37 (64.9%) at discontinuation.Discussion: Biologic DMARD discontinuations identified in the healthcare administrative databasese of Tuscany are frequently observed in situations of controlled RA disease. Further studies are warranted to confirm that these events can be used in studies using healthcare administrative databases as proxies of treatment effectiveness.</p
    corecore